Eli Lilly and Company (LLY)

NYQ – Real Time Price. Currency in USD

989.87

+22.88 (2.37%)

At close: May 12, 2026, 4:00 PM EDT

990.68

+0.81 (0.08%)

After-hours: May 12, 2026, 7:59 PM EDT

11.05.2026

Pfizer vs Eli Lilly: Different Bets on Pharma M&A

Pfizer (NYSE: PFE | PFE Price Prediction) and Eli Lilly (NYSE: LLY) recently reported quarterly results that read like two scripts from opposite ends of pharma.

11.05.2026

NYSE Content Update: Eli Lilly to Celebrate 150 Years of Scientific Innovation

NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, May 11, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor.

10.05.2026

AI, Obesity Drugs, and Diagnostics Fuel Healthcare Growth

Healthcare is regaining momentum as innovation—especially AI‑driven drug discovery—creates new growth opportunities, according to Shivani Vohra. She points to obesity treatments from Eli Lilly (LLY) and Novo Nordisk (NVO), advances in diagnostics from Natera (NTRA), and continued strength in med tech leaders like Intuitive Surgical (ISRG) and Edwards Lifesciences (EW) as key areas of expansion.

10.05.2026

Eli Lilly: 'Strong Buy' Raised Revenue Guidance By $2 Billion For 2026 And Label Expansions

Eli Lilly remains a 'strong buy' as I see robust revenue growth across obesity, diabetes, immunology, and oncology franchises. LLY's MOUNJARO and ZEPBOUND delivered Q1 2026 revenues of $8.66B [+125%] and $4.16B [+80%] respectively, driving a 56% YoY total revenue increase. Pipeline momentum is strong: FOUNDAYO launched, Retatrutide and Eloralintide advanced, and EBGLYSS/JAYPIRCA show double-digit growth with label expansion catalysts ahead.

08.05.2026

Lilly's obesity pill tops 7,000 prescriptions in fourth week, signals modest uptake

Eli Lilly's new oral weight-loss drug, Foundayo, was prescribed 7,335 times in the U.S. in the fourth week, a modest uptake compared to rival ‌Novo Nordisk's Wegovy pill, analysts said.

08.05.2026

Eli Lilly's Retatrutide Is So Hot, The Unlaunched Weight-Loss Drug Is Already Getting Knocked Off

Eli Lilly is just wrapping up trials of its retatrutide, but consumers already are flocking to black-market versions. Can Lilly compete with copies of its own drug?

07.05.2026

How This Eli Lilly-Tied IPO Stock Fared In Its First Quarter

IPO stock Omada Health easily beat first-quarter sales expectations Thursday, and announced a deal with drug titan Eli Lilly.

Videos

10.05.2026

Positive

AI, Obesity Drugs, and Diagnostics Fuel Healthcare Growth

07.05.2026

Positive

Retatrutide Black Market: Why Consumers Will Do Anything To Get Eli Lilly's New GLP

30.04.2026

Positive

Eli Lilly CEO on new GLP-1 pill: It's been out 20 days and we have over 20,000 patients

30.04.2026

Positive

QCOM Rally, RCL Regains Bookings Pace, LLY Soars

Upgrades / Downgrades

Ticker	Brokerage Firm	Ratings Change	Price Target	Date
LLY	HSBC Securities	Reduce	undefined >> $850	March 17th 2026
LLY	RBC Capital Mkts	Outperform	undefined >> $1,250	February 25th 2026
LLY	Barclays	Overweight	undefined >> $1,350	February 20th 2026
LLY	UBS	Buy	undefined >> $1,250	January 7th 2026
LLY	Daiwa Securities	Buy	undefined >> $1,230	December 16th 2025
LLY	Goldman	Buy	$951 >> $1,145	December 15th 2025
LLY	BofA Securities	Buy	$1,286 >> $1,268	December 15th 2025
LLY	Scotiabank	Sector Outperform	undefined >> $1,165	November 13th 2025

Press releases

11.05.2026

NYSE Content Update: Eli Lilly to Celebrate 150 Years of Scientific Innovation

06.05.2026

Lilly commits additional $4.5 billion across Indiana manufacturing sites, opens first dedicated genetic medicine facility

Lilly's capital commitments to expand manufacturing in its home state now total $21 billion since 2020 Lilly Lebanon Advanced Therapies opens as company's first dedicated genetic medicine manufacturing facility LEBANON, Ind., May 6, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced an additional $4.5 billion investment across two of its three Lebanon sites—bringing the company's total Indiana capital expansion commitments since 2020 to more than $21 billion.

05.05.2026

Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 to demonstrate durable disease clearance in ulcerative colitis through four years

In LUCENT-3, more than 60% of patients who achieved disease clearance at one year maintained it after four years of continuous Omvoh treatment Disease clearance is a high clinical bar in UC requiring simultaneous symptomatic, endoscopic and histologic remission INDIANAPOLIS, May 5, 2026 /PRNewswire/ -- New long-term data from Eli Lilly and Company (NYSE: LLY) show patients with moderately to severely active ulcerative colitis (UC) treated with Omvoh (mirikizumab-mrkz) achieved durable disease clearance through four years of continuous treatment. In the LUCENT-3 open-label extension study, 63.5% of Omvoh-treated patients who achieved disease clearance at one year sustained it at four years.

04.05.2026

Lilly declares second-quarter 2026 dividend

INDIANAPOLIS, May 4, 2026 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2026 of $1.73 per share on outstanding common stock. The dividend is payable on June 10, 2026, to shareholders of record at the close of business on May 15, 2026.

Eli Lilly and Company (LLY)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Eli Lilly and Company (LLY)

Pfizer vs Eli Lilly: Different Bets on Pharma M&A

NYSE Content Update: Eli Lilly to Celebrate 150 Years of Scientific Innovation

AI, Obesity Drugs, and Diagnostics Fuel Healthcare Growth

Eli Lilly: 'Strong Buy' Raised Revenue Guidance By $2 Billion For 2026 And Label Expansions

Lilly's obesity pill tops 7,000 prescriptions in fourth week, signals modest uptake

Eli Lilly's Retatrutide Is So Hot, The Unlaunched Weight-Loss Drug Is Already Getting Knocked Off